Avian Influenza (Bird Flu) Differential Diagnoses

1. Tanner WD, Toth DJ, Gundlapalli AV. The pandemic potential of avian influenza A(H7N9) virus: a review. Epidemiol Infect. 2015 Dec. 143 (16):3359-74. [Medline].

2. Hulse-Post DJ, Sturm-Ramirez KM, Humberd J, Seiler P, Govorkova EA, Krauss S, et al. Role of domestic ducks in the propagation and biological evolution of highly pathogenic H5N1 influenza viruses in Asia. Proc Natl Acad Sci U S A. 2005 Jul 26. 102 (30):10682-7. [Medline].

3. World Health Organization. H5N1 avian influenza: Timeline of major events. World Health Organization. Available at http://www.who.int/csr/disease/avian_influenza/Timeline_2007_03_20.pdf. Accessed: October 2007.

4. Kayali G, Kandeil A, El-Shesheny R, Kayed AS, Maatouq AM, Cai Z, et al. Avian Influenza A(H5N1) Virus in Egypt. Emerg Infect Dis. 2016 Mar. 22 (3):379-88. [Medline]. [Full Text].

5. World Health Organization. Influenza (Avian and other zoonotic). WHO. Available at https://www.who.int/news-room/fact-sheets/detail/influenza-(avian-and-other-zoonotic). November 13, 2018; Accessed: April 8, 2019.

6. Ungchusak K, Auewarakul P, Dowell SF, Kitphati R, Auwanit W, Puthavathana P, et al. Probable person-to-person transmission of avian influenza A (H5N1). N Engl J Med. 2005 Jan 27. 352 (4):333-40. [Medline].

7. Hoheisel G, Luk WK, Winkler J, Wirtz H, Gillissen A, Hui DS, et al. [Avian influenza and the Severe Acute Respiratory Syndrome (SARS) - experiences and perspectives]. Pneumologie. 2007 Jan. 61 (1):41-5. [Medline].

8. Nicholls JM, Chan MC, Chan WY, Wong HK, Cheung CY, Kwong DL, et al. Tropism of avian influenza A (H5N1) in the upper and lower respiratory tract. Nat Med. 2007 Feb. 13 (2):147-9. [Medline].

9. Chen GW, Chang SC, Mok CK, Lo YL, Kung YN, Huang JH, et al. Genomic signatures of human versus avian influenza A viruses. Emerg Infect Dis. 2006 Sep. 12 (9):1353-60. [Medline].

10. Centers for Disease Control and Prevention. Key Facts About Seasonal Influenza (Flu). Centers for Disease Control and Prevention. Available at http://www.cdc.gov/flu/keyfacts.htm. Accessed: October 2007.

11. World Health Organization. Confirmed Human Cases of Avian Influenza A(H5N1). World Health Organization. Available at http://wpro.who.int/emerging_diseases/AvianInfluenza/en. Accessed: August 2015.

12. Kato YS, Fukui K, Suzuki K. Mechanism of a Mutation in Non-Structural Protein 1 Inducing High Pathogenicity of Avian Influenza Virus H5N1. Protein Pept Lett. 2016. 23 (4):372-8. [Medline].

13. Dudley JP. Age-specific infection and death rates for human A(H5N1) avian influenza in Egypt. Euro Surveill. 2009 May 7. 14 (18):[Medline].

14. World Health Organization. Clinical management of human infection with avian influenza A (H5N1) virus. Available at. World Health Organization. Available at http://www.who.int/influenza/resources/documents/ClinicalManagement07.pdf. Accessed: August 2015.

15. Taniguchi K, Ando Y, Nobori H, Toba S, Noshi T, Kobayashi M, et al. Inhibition of avian-origin influenza A(H7N9) virus by the novel cap-dependent endonuclease inhibitor baloxavir marboxil. Sci Rep. 2019 Mar 5. 9 (1):3466. [Medline].

16. US Food and Drug Administration. H5N1 Influenza Virus Vaccine. US Food and Drug Administration. Available at http://www.fda.gov/biologicsbloodvaccines/vaccines/questionsaboutvaccines/ucm080753.htm. Accessed: August 2015.

17. Belshe RB, Frey SE, Graham I, Mulligan MJ, Edupuganti S, Jackson LA, et al. Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant. J Infect Dis. 2011 Mar 1. 203 (5):666-73. [Medline].

18. Centers for Disease Control and Prevention. Interim Guidance on the Use of Antiviral Medications for Treatment of Human Infections with Novel Influenza A Viruses Associated with Severe Human Disease. Centers for Disease Control and Prevention. Available at http://www.cdc.gov/flu/avianflu/novel-av-treatment-guidance.htm. Accessed: August 2015.

19. Hill G, Cihlar T, Oo C, Ho ES, Prior K, Wiltshire H, et al. The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies. Drug Metab Dispos. 2002 Jan. 30 (1):13-9. [Medline].

20. Auewarakul P, Suptawiwat O, Kongchanagul A, Sangma C, Suzuki Y, Ungchusak K, et al. An avian influenza H5N1 virus that binds to a human-type receptor. J Virol. 2007 Sep. 81 (18):9950-5. [Medline].

21. Beigel JH, Farrar J, Han AM, Hayden FG, Hyer R, de Jong MD, et al. Avian influenza A (H5N1) infection in humans. N Engl J Med. 2005 Sep 29. 353 (13):1374-85. [Medline].

22. Chen H, Smith GJ, Zhang SY, Qin K, Wang J, Li KS, et al. Avian flu: H5N1 virus outbreak in migratory waterfowl. Nature. 2005 Jul 14. 436 (7048):191-2. [Medline].

23. Finkelstein DB, Mukatira S, Mehta PK, Obenauer JC, Su X, Webster RG, et al. Persistent host markers in pandemic and H5N1 influenza viruses. J Virol. 2007 Oct. 81 (19):10292-9. [Medline].

24. Shi D, Yang J, Yang D, LeCluyse EL, Black C, You L, et al. Anti-influenza prodrug oseltamivir is activated by carboxylesterase human carboxylesterase 1, and the activation is inhibited by antiplatelet agent clopidogrel. J Pharmacol Exp Ther. 2006 Dec. 319 (3):1477-84. [Medline].

Nicholas John Bennett, MBBCh, PhD, MA(Cantab), FAAP Assistant Professor of Pediatrics, Co-Director of Antimicrobial Stewardship, Medical Director, Division of Pediatric Infectious Diseases and Immunology, Connecticut Children's Medical Center

Nicholas John Bennett, MBBCh, PhD, MA(Cantab), FAAP is a member of the following medical societies: Alpha Omega Alpha, American Academy of Pediatrics

Disclosure: Received research grant from: Cubist<br/>Received income in an amount equal to or greater than $250 from: Horizon Pharmaceuticals, Shire<br/>Medico legal consulting for: Various.

Joseph Domachowske, MD Professor of Pediatrics, Microbiology and Immunology, Department of Pediatrics, Division of Infectious Diseases, State University of New York Upstate Medical University

Joseph Domachowske, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Pediatrics, American Society for Microbiology, Infectious Diseases Society of America, Pediatric Infectious Diseases Society, Phi Beta Kappa

Disclosure: Received research grant from: Pfizer;GlaxoSmithKline;AstraZeneca;Merck;American Academy of Pediatrics, Novavax, Regeneron, Diassess, Actelion<br/>Received income in an amount equal to or greater than $250 from: Sanofi Pasteur.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Michael Stuart Bronze, MD David Ross Boyd Professor and Chairman, Department of Medicine, Stewart G Wolf Endowed Chair in Internal Medicine, Department of Medicine, University of Oklahoma Health Science Center; Master of the American College of Physicians; Fellow, Infectious Diseases Society of America; Fellow of the Royal College of Physicians, London

Michael Stuart Bronze, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians, American Medical Association, Association of Professors of Medicine, Infectious Diseases Society of America, Oklahoma State Medical Association, Southern Society for Clinical Investigation

Disclosure: Nothing to disclose.

• Print this section
• Print the entire contents of
• Print the entire contents of article